2.225
price up icon17.84%   0.375
 
loading
Schlusskurs vom Vortag:
$1.85
Offen:
$1.89
24-Stunden-Volumen:
1.50M
Relative Volume:
1.06
Marktkapitalisierung:
$121.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.50M
KGV:
-0.9271
EPS:
-2.4
Netto-Cashflow:
$-114.31M
1W Leistung:
+27.49%
1M Leistung:
+45.33%
6M Leistung:
-47.60%
1J Leistung:
-70.50%
1-Tages-Spanne:
Value
$1.89
$2.205
1-Wochen-Bereich:
Value
$1.6706
$2.20
52-Wochen-Spanne:
Value
$1.31
$8.33

Nkarta Inc Stock (NKTX) Company Profile

Name
Firmenname
Nkarta Inc
Name
Telefon
(925) 407-1049
Name
Adresse
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Name
Mitarbeiter
157
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
NKTX's Discussions on Twitter

Vergleichen Sie NKTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NKTX
Nkarta Inc
2.20 121.34M 0 -117.50M -114.31M -2.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
488.61 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
582.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.96 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.29 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
253.14 26.16B 3.81B -644.79M -669.77M -6.24

Nkarta Inc Stock (NKTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-09 Eingeleitet Rodman & Renshaw Buy
2024-08-14 Hochstufung Raymond James Outperform → Strong Buy
2024-03-22 Herabstufung Raymond James Strong Buy → Outperform
2022-12-22 Herabstufung Oppenheimer Outperform → Perform
2022-10-10 Eingeleitet Canaccord Genuity Buy
2022-07-28 Eingeleitet Needham Buy
2022-07-18 Eingeleitet SVB Leerink Outperform
2022-03-11 Eingeleitet Raymond James Outperform
2022-03-08 Eingeleitet H.C. Wainwright Buy
2022-01-06 Eingeleitet William Blair Outperform
2021-11-18 Eingeleitet SMBC Nikko Outperform
2021-07-16 Eingeleitet Oppenheimer Outperform
2020-08-04 Eingeleitet Cowen Outperform
2020-08-04 Eingeleitet Evercore ISI Outperform
2020-08-04 Eingeleitet Mizuho Buy
2020-08-04 Eingeleitet Stifel Buy
Alle ansehen

Nkarta Inc Aktie (NKTX) Neueste Nachrichten

pulisher
Apr 21, 2025

Nkarta, Inc. (NASDAQ:NKTX) Receives Average Rating of “Buy” from Brokerages - Defense World

Apr 21, 2025
pulisher
Apr 18, 2025

JPMorgan Chase & Co. Raises Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 18, 2025
pulisher
Apr 16, 2025

Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace

Apr 16, 2025
pulisher
Apr 15, 2025

Wellington Management Group LLP Boosts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Nkarta (NKTX) Upgraded to Buy: Here's Why - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

Natural Killer Cell Therapy Market Hits New High | Major Giants Nkarta Therapeutics, Kiadis Pharma - newstrail.com

Apr 14, 2025
pulisher
Apr 14, 2025

American Century Companies Inc. Buys 7,378 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Sei Investments Co. Invests $57,000 in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Nkarta’s (NKTX) Buy Rating Reiterated at Needham & Company LLC - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Nkarta (NASDAQ:NKTX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Apr 11, 2025
pulisher
Apr 11, 2025

Prudential Financial Inc. Sells 49,500 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 11, 2025
pulisher
Apr 05, 2025

Thrivent Financial for Lutherans Makes New Investment in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 05, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Cuts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Nkarta to Participate in an April Investor Conference - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Leerink Partnrs Has Bullish Outlook for Nkarta Q1 Earnings - The AM Reporter

Apr 01, 2025
pulisher
Mar 31, 2025

Nkarta: Grinding Lower, Trying To Find Support (NASDAQ:NKTX) - Seeking Alpha

Mar 31, 2025
pulisher
Mar 31, 2025

Nkarta: Betting On The Turnaround (NASDAQ:NKTX) - Seeking Alpha

Mar 31, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Forecast for Nkarta Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

William Blair Estimates Nkarta’s Q1 Earnings (NASDAQ:NKTX) - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Nkarta, Inc. (NASDAQ:NKTX) Receives $14.86 Average Price Target from Brokerages - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

What is HC Wainwright’s Forecast for Nkarta Q4 Earnings? - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Nkarta (NASDAQ:NKTX) - Defense World

Mar 29, 2025
pulisher
Mar 27, 2025

Nkarta’s Strategic Workforce Reduction and Clinical Progress Justify Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı

Mar 27, 2025
pulisher
Mar 27, 2025

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy - BioPharma Dive

Mar 27, 2025
pulisher
Mar 27, 2025

Stifel cuts Nkarta stock price target to $14, maintains buy rating - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News

Mar 27, 2025
pulisher
Mar 27, 2025

H.C. Wainwright maintains Buy on Nkarta stock with $18 target By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

H.C. Wainwright maintains Buy on Nkarta stock with $18 target - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Nkarta lays off 3rd of staff to fund autoimmune CAR NK program - Fierce Biotech

Mar 27, 2025
pulisher
Mar 27, 2025

Newly pivoted to autoimmune, Nkarta trims staff by over third - FirstWord Pharma

Mar 27, 2025
pulisher
Mar 27, 2025

Nkarta’s Strategic Restructuring and NKX019 Progress Drive Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 26, 2025

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta Posts Narrower Q4 Loss; Discloses Restructuring Plan - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta Announces Major Restructuring and Leadership Changes - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta Inc To Reduce Workforce By 34%, Impacting 53 PositionsSEC Filing - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta's Strategic Reset: 34% Staff Cut Powers 5-Year Cash Runway with $380M War Chest - Stock Titan

Mar 26, 2025
pulisher
Mar 26, 2025

TD Cowen Keeps Their Buy Rating on Nkarta (NKTX) - The Globe and Mail

Mar 26, 2025
pulisher
Mar 21, 2025

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - MSN

Mar 21, 2025
pulisher
Mar 20, 2025

Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Mar 20, 2025
pulisher
Mar 19, 2025

Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Mar 19, 2025
pulisher
Mar 17, 2025

Nkarta Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView

Mar 17, 2025

Finanzdaten der Nkarta Inc-Aktie (NKTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Nkarta Inc-Aktie (NKTX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Levin Alyssa
See Remarks
Jan 15 '25
Sale
2.20
5,838
12,844
102,662
Brandenberger Ralph
Chief Technical Officer
Jan 15 '25
Sale
2.20
7,447
16,383
124,796
HASTINGS PAUL J
Chief Executive Officer
Jan 15 '25
Sale
2.20
17,378
38,232
319,859
Hager Alicia J.
Chief Legal Officer
Jan 15 '25
Sale
2.20
9,584
21,085
146,735
Hager Alicia J.
Chief Legal Officer
Jul 16 '24
Sale
8.00
3,396
27,168
103,819
Trager James
Chief Scientific Officer
Jun 18 '24
Sale
5.60
456
2,554
150,959
HASTINGS PAUL J
Chief Executive Officer
Jun 18 '24
Sale
5.60
1,770
9,912
240,737
Shook David
Chief Medical Officer
Jun 18 '24
Sale
5.60
456
2,554
116,524
Hager Alicia J.
Chief Legal Officer
Jun 18 '24
Sale
5.60
727
4,071
107,215
Brandenberger Ralph
Chief Technical Officer
Jun 18 '24
Sale
5.60
229
1,282
79,743
$19.80
price down icon 1.75%
$70.30
price up icon 2.22%
$32.51
price up icon 0.87%
$26.24
price up icon 1.84%
$102.53
price down icon 0.01%
biotechnology ONC
$248.35
price up icon 8.46%
Kapitalisierung:     |  Volumen (24h):